Globus Medical (NYSE:GMED) Issues FY 2026 Earnings Guidance

Globus Medical (NYSE:GMED) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 4.700-4.800 for the period, compared to the consensus EPS estimate of 4.470. The company issued revenue guidance of $3.2 billion-$3.2 billion, compared to the consensus revenue estimate of $3.2 billion.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Canaccord Genuity Group raised their price target on shares of Globus Medical from $105.00 to $112.00 and gave the company a “buy” rating in a research report on Friday, January 9th. Needham & Company LLC lifted their target price on shares of Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research report on Friday. Barclays lifted their target price on shares of Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Wall Street Zen lowered shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Finally, Royal Bank Of Canada lifted their price target on shares of Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a research report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $106.36.

Globus Medical Trading Down 8.5%

NYSE GMED opened at $77.81 on Friday. The company’s fifty day simple moving average is $89.86 and its 200-day simple moving average is $86.65. Globus Medical has a 52 week low of $51.79 and a 52 week high of $101.40. The stock has a market cap of $10.52 billion, a P/E ratio of 18.10, a PEG ratio of 1.99 and a beta of 1.00.

Globus Medical (NYSE:GMED) last posted its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.20. The firm had revenue of $759.85 million for the quarter, compared to analysts’ expectations of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.69%. The firm’s quarterly revenue was up 27.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.68 earnings per share. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, research analysts expect that Globus Medical will post 4.46 EPS for the current fiscal year.

Insider Transactions at Globus Medical

In related news, EVP Kelly Huller sold 20,000 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total value of $1,890,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 18.38% of the stock is owned by corporate insiders.

Key Globus Medical News

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Globus Medical beat Q1 expectations on both earnings and revenue, reporting $1.12 EPS versus $0.92 expected and $759.9 million in sales versus $740.4 million expected; revenue rose 27% year over year and margins improved. Article Title
• Positive Sentiment: The company also raised FY2026 EPS guidance to $4.70-$4.80, above consensus, signaling management confidence in continued growth. Article Title
• Positive Sentiment: Royal Bank of Canada lifted its price target on GMED to $120 from $115 and kept an outperform rating, while Needham raised its target to $117 from $114 and reiterated a buy rating, reflecting bullish analyst sentiment. Article Title
• Neutral Sentiment: Investors are also digesting the company’s Q1 earnings call transcript and related post-earnings coverage, which primarily reinforce the strong results rather than adding new catalysts. Article Title
• Negative Sentiment: Despite the beat and higher guidance, the stock has sold off as traders appear to be taking profits and focusing on expectations that were already elevated going into the report. Article Title

Institutional Trading of Globus Medical

Several institutional investors have recently added to or reduced their stakes in the business. Invesco Ltd. increased its stake in Globus Medical by 1,235.2% during the fourth quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock valued at $339,322,000 after purchasing an additional 3,595,339 shares during the last quarter. Corient Private Wealth LLC grew its position in shares of Globus Medical by 87.4% during the fourth quarter. Corient Private Wealth LLC now owns 89,916 shares of the medical device company’s stock worth $7,851,000 after acquiring an additional 41,934 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new position in shares of Globus Medical during the fourth quarter worth about $499,000. EP Wealth Advisors LLC bought a new position in shares of Globus Medical during the fourth quarter worth about $607,000. Finally, Fuller & Thaler Asset Management Inc. bought a new position in shares of Globus Medical during the fourth quarter worth about $90,411,000. Institutional investors own 95.16% of the company’s stock.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.